Freezing treatment for early-stage breast cancer
Cryoablation as a Minimally Invasive Alternative to Surgery for Managing Ductal Carcinoma In Situ
NA · Glendale Adventist Medical Center d/b/a Adventist Health Glendale · NCT05218044
This study tests if freezing treatment can be a safe and effective alternative to surgery for people with early-stage breast cancer called ductal carcinoma in situ.
Quick facts
| Phase | NA |
|---|---|
| Study type | Interventional |
| Enrollment | 30 (estimated) |
| Ages | 18 Years and up |
| Sex | Female |
| Sponsor | Glendale Adventist Medical Center d/b/a Adventist Health Glendale (other) |
| Drugs / interventions | radiation |
| Locations | 1 site (Glendale, California) |
| Trial ID | NCT05218044 on ClinicalTrials.gov |
What this trial studies
This clinical trial evaluates cryoablation, a minimally invasive procedure that freezes tumor cells, as an alternative to surgery for managing ductal carcinoma in situ (DCIS). The study focuses on patients with small areas of DCIS, assessing the effectiveness of cryoablation in achieving complete ablation within the targeted area. Participants will undergo this office-based procedure, which aims to provide a cost-effective treatment option while minimizing recovery time and surgical risks.
Who should consider this trial
Good fit: Ideal candidates are individuals diagnosed with DCIS measuring 2 cm or less, with no prior history of breast cancer or surgical interventions in the affected breast.
Not a fit: Patients with larger DCIS lesions, previous breast cancer history, or those who have undergone surgical procedures in the same breast may not benefit from this study.
Why it matters
Potential benefit: If successful, this approach could offer patients a less invasive treatment option with reduced recovery times and fewer complications.
How similar studies have performed: While cryoablation is being explored for various breast cancer treatments, this specific application for DCIS is relatively novel and has not been extensively tested in prior studies.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * DCIS spanning 2 cm or less based on its radiographic appearance by mammography and/or breast contrast-enhanced MRI * Diagnosis of DCIS by minimally invasive needle biopsy * No prior history of DCIS or invasive breast cancer in the same breast * No history of surgical biopsy and/or lumpectomy for diagnosis/treatment in the same breast * Adequate breast volume and skin clearance to permit cryoablation as assessed by Dr. Holmes. This excludes male and females with breasts too small to allow safe cryoablation * Non-pregnant, non-lactating, and no history of pregnancy within the preceding 6 months * No history of breast radiation in the same breast
Where this trial is running
Glendale, California
- Office of Dennis R. Holmes, M.D., F.A.C.S. — Glendale, California, United States (RECRUITING)
Study contacts
- Study coordinator: Dennis R Holmes, M.D.
- Email: drholmesmd50@gmail.com
- Phone: 800-203-5515
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.
Conditions: Ductal Carcinoma in Situ, DCIS